ライフサイエンスコーパス: histoplasmosis

1 ncy were reclassified as benign (thymoma and histoplasmosis).

2 is, chronic herpes simplex, and disseminated histoplasmosis).

3 ncover how innate immunity modulation alters histoplasmosis.

4 nction, resulting in an inability to control histoplasmosis.

5 e existence a regulatory IL-17/IL-23 axis in histoplasmosis.

6 ectious complications including disseminated histoplasmosis.

7 y represents a strategy of immunotherapy for histoplasmosis.

8 capsulatum, a pathogenic fungus that causes histoplasmosis.

9 ct on host resistance in mice with secondary histoplasmosis.

10 aling has on host defenses against pulmonary histoplasmosis.

11 The same is true for histoplasmosis.

12 surgery, one had arm cellulitis, and one had histoplasmosis.

13 IL-4 in the lung on the course of pulmonary histoplasmosis.

14 and mycological tests to accurately diagnose histoplasmosis.

15 , subverted protective immunity in secondary histoplasmosis.

16 rapy are at risk for developing disseminated histoplasmosis.

17 similar role to play in the pathogenesis of histoplasmosis.

18 igen to protect mice in a model of pulmonary histoplasmosis.

19 n the lungs of C57BL/6 mice with reinfection histoplasmosis.

20 en these receptors for regulation reexposure histoplasmosis.

21 means of diagnosing the more severe forms of histoplasmosis.

22 he course of primary and secondary pulmonary histoplasmosis.

23 ferences in control of primary and secondary histoplasmosis.

24 with sera of healthy patients or those with histoplasmosis.

25 ntinued in 1 patient because of disseminated histoplasmosis.

26 of a protective immune response in pulmonary histoplasmosis.

27 opment of specific serodiagnostic assays for histoplasmosis.

28 se with different clinical manifestations of histoplasmosis.

29 s agent as a possible adjunctive therapy for histoplasmosis.

30 a frequently relied-on approach to diagnose histoplasmosis.

31 ion of the fungal diseases blastomycosis and histoplasmosis.

32 nt visit) and suspected (1 outpatient visit) histoplasmosis.

33 etween length of time on IMT and the risk of histoplasmosis.

34 for ocular inflammation but did not develop histoplasmosis.

35 x-matched control cohort who did not develop histoplasmosis.

36 ients died, and there were no recurrences of histoplasmosis.

37 herapy may develop pulmonary or disseminated histoplasmosis.

38 eeded for pneumocystosis, talaromycosis, and histoplasmosis.

39 imal method for diagnosis of acute pulmonary histoplasmosis.

40 e most sensitive and rapid means to diagnose histoplasmosis.

41 locker therapy after successful treatment of histoplasmosis.

42 a virulence in a murine model of respiratory histoplasmosis.

43 UAg) detection is an important biomarker for histoplasmosis.

44 r during lung infection in a murine model of histoplasmosis.

45 ility of Cfp4 as a diagnostic exoantigen for histoplasmosis.

46 after SOT is the period of highest risk for histoplasmosis.

47 series of patients undergoing treatment for histoplasmosis.

48 ere disease were risk factors for death from histoplasmosis.

49 the interplay between TNF-alpha and CCR5 in histoplasmosis.

50 reactions occurred in 96.3% of patients with histoplasmosis, 100% of patients with paracoccidioidomyc

51 cidioidomycosis (31.4%) and less common with histoplasmosis (14.0%) and blastomycosis (13.1%) versus

52 cidioidomycosis (31.4%) and less common with histoplasmosis (14.0%) and blastomycosis (13.1%) vs. inf

53 t reactivity with sera from 20 patients with histoplasmosis, 15 patients with blastomycosis, and 14 h

54 There were 79 749 histoplasmosis, 37 726 coccidioidomycosis, and 6109 blas

55 We immunologically characterized 10 cases of histoplasmosis, 4 of whom developed histoplasmosis IRIS.

56 ver was less common in blastomycosis (2.6%), histoplasmosis (5.3%) and coccidioidomycosis (9.4%) than

57 ver was less common in blastomycosis (2.6%), histoplasmosis (5.3%), and coccidioidomycosis (9.4%) tha

58 ; cryptococcosis, 76% and 4 (5.80/1.35); and histoplasmosis, 68% and 6 (1.36/0.23).

59 above the clinically relevant threshold for histoplasmosis, 69% (35/51) for coccidioidomycosis, and

60 Of the 10 patients with histoplasmosis, 9 required treatment in an intensive car

61 Histoplasmosis, a fungal disease endemic in sub-Saharan

62 Furthermore, in secondary histoplasmosis, a sharp contrast can be drawn between lu

63 Histoplasmosis, a systemic mycosis caused by the fungus

64 ent, diagnosis, and outcomes associated with histoplasmosis after solid organ transplant (SOT), we re

65 onal study examining patients that developed histoplasmosis after the initiation of systemic immunomo

66 In a lethal model of histoplasmosis, all PD-1-deficient mice survived infecti

67 ed blastomycosis and one from a patient with histoplasmosis (also positive by the MiraVista Blastomyc

68 In December 1993, four reported cases of histoplasmosis among employees in a Michigan pulp paper

69 to provide the first prevalence estimates of histoplasmosis among individuals with advanced HIV in Co

70 the development of disseminated or pulmonary histoplasmosis among patients who are receiving systemic

71 des for symptoms or findings consistent with histoplasmosis and 35% had >=2 healthcare visits in the

72 lting in two (3.3%) deaths from disseminated histoplasmosis and a herpes virus infection.

73 Approaches to the diagnosis of histoplasmosis and areas that require further research w

74 amed after the etiologic agent, for example, histoplasmosis and aspergillosis, while this should not

75 efined as 100 cases/100 000 person-years for histoplasmosis and coccidioidomycosis and 50 cases/100 0

76 of serum from patients with acute pulmonary histoplasmosis and controls in the MVista Histoplasma an

77 specimens from patients with culture-proven histoplasmosis and controls were tested using both metho

78 neovascularization caused by presumed ocular histoplasmosis and demonstrated stabilization of the cho

79 rement can be useful for diagnosing systemic histoplasmosis and for monitoring treatment response, es

80 ing the initial host-pathogen interaction in histoplasmosis and have revealed an important mechanism

81 f participants with progressive disseminated histoplasmosis and respiratory symptoms had a positive B

82 choroidal neovascular membrane due to ocular histoplasmosis and to provide a treatment algorithm.

83 its reactivity with sera from patients with histoplasmosis and, to lesser extent, blastomycosis.

84 ns (cryptococcosis), Histoplasma capsulatum (histoplasmosis), and Talaromyces (Penicillium) marneffei

85 Coccidioidomycosis, histoplasmosis, and blastomycosis are underrecognized an

86 arget of the cellular immune response during histoplasmosis, and immunization with this protein is pr

87 diate protection in a murine model of lethal histoplasmosis, and it suggests a new candidate antigen

88 omaviruses, and fungal infections, primarily histoplasmosis, and molds.

89 0 confers a salutary effect on the course of histoplasmosis, and the beneficial effects of IL-10 defi

90 Nine of these patients had histoplasmosis, and the Gotham and MiraVista EIAs yielde

91 3%) had any fungal-specific laboratory test: histoplasmosis antibody test (n = 349 [18%]), Histoplasm

92 is, and Histoplasma capsulatum, the agent of histoplasmosis, are known to form meiotic (sexual) stage

93 will likely be of benefit in presumed ocular histoplasmosis associated choroidal neovascularization.

94 In patients with moderate to severe histoplasmosis associated with AIDS, the preferred treat

95 Patients' last histoplasmosis-associated healthcare visits occurred a m

96 histoplasmosis has a worldwide distribution, histoplasmosis-associated immune reconstitution inflamma

97 ed to describe the incidence and features of histoplasmosis-associated IRIS in a cohort of PLHIV.

98 Histoplasmosis-associated IRIS incidence was low but gen

99 Twenty-two cases of histoplasmosis-associated IRIS were included (14 infecti

100 detection in patients with culture-confirmed histoplasmosis at Mayo Clinic (Rochester, MN) over a 10-

101 equently developed pulmonary or disseminated histoplasmosis at the Mayo Clinic in Rochester, Minnesot

102 of fever and signs/symptoms attributable to histoplasmosis) at day 14.

103 ide (25.0%) versus outside (28.7%) the U.S. "histoplasmosis belt." Aggregate sensitivity was 96.5% fo

104 pective review of 98 patients diagnosed with histoplasmosis between January 2000 and June 2011.

105 Clinical differences in histoplasmosis between North America and Brazil prompted

106 strongyloidiasis, malaria, schistosomiasis, histoplasmosis, blastomycosis, and coccidioidomycosis.

107 tion against use of AmB+Flu for treatment of histoplasmosis, but studies of the effect of treatment o

108 ing regulates pathogen persistence in murine histoplasmosis by regulating Tregs exiting from the thym

109 Histoplasmosis can be challenging to diagnose and is wid

110 Acute pulmonary histoplasmosis can be severe, especially following heavy

111 Both paracoccidioidomycosis and histoplasmosis can mimic several infectious and non-infe

112 We identified incident blastomycosis and histoplasmosis cases from 2013 to 2023 within Oracle EHR

113 Blastomycosis, coccidioidomycosis, and histoplasmosis cause various symptoms and syndromes, whi

114 Histoplasmosis caused by Histoplasma capsulatum var. dub

115 cid sensor that can identify the presence of histoplasmosis causing fungal genes, in whole blood or b

116 Persons with histoplasmosis, coccidioidomycosis, and blastomycosis ar

117 The primary outcome was the incidence of histoplasmosis, coccidioidomycosis, and blastomycosis fo

118 Diagnoses of histoplasmosis, coccidioidomycosis, and blastomycosis we

119 We present a case of disseminated histoplasmosis, complicated by retroperitoneal bleeding

120 nd from biopsy specimens from a patient with histoplasmosis contained fungal cells that were labeled

121 ed stored urine from patients diagnosed with histoplasmosis during an outbreak in Indianapolis which

122 and may indicate higher risk of disseminated histoplasmosis, especially in HIV infected patients.

123 pdate on findings concerning presumed ocular histoplasmosis etiology, epidemiology, and pathophysiolo

124 We identified 261 cases of histoplasmosis from 2002 to 2017.

125 tive cohort of adult patients diagnosed with histoplasmosis from 2002 to 2017.

126 tive cohort of adult patients diagnosed with histoplasmosis from 2002 to 2017.

127 of-concept study may aid in the diagnosis of histoplasmosis from FFPE tissue.

128 stating vision loss that may occur in ocular histoplasmosis from the development of an atrophic scar

129 mine if IFN-gamma is necessary in reexposure histoplasmosis, GKO and WT mice were inoculated with 10(

130 Although histoplasmosis has a worldwide distribution, histoplasmo

131 Since disseminated histoplasmosis has emerged as a difficult clinical entit

132 zoster virus (HR, 1.49 [95% CI, 1.18-1.89]), histoplasmosis (HR, 3.55 [95% CI, 1.10-11.42]), and Pneu

133 e limited data regarding the pathogenesis of histoplasmosis immune reconstitution inflammatory syndro

134 y with L-AmB versus control for disseminated histoplasmosis in AIDS, followed by oral itraconazole th

135 on may be a mechanism for the development of histoplasmosis in AIDS.

136 with acquired immunodeficiency syndrome and histoplasmosis in Brazil and United States were compared

137 igen that may be useful for the diagnosis of histoplasmosis in humans.

138 While pulmonary involvement of histoplasmosis in immune-suppressed patients is common,

139 omodulatory effects of IL-12 on disseminated histoplasmosis in immunodeficient SCID mice.

140 -gamma is requisite for control of pulmonary histoplasmosis in naive and reexposed mice.

141 fy all reports received through July 2001 of histoplasmosis in patients treated with either inflixima

142 modulates the protective immune response to histoplasmosis in SCID mice and also suggests that IL-12

143 All cases of histoplasmosis in SOT recipients diagnosed between 1 Jan

144 Itraconazole is the preferred azole for histoplasmosis in the current Infectious Diseases Societ

145 Clinicians should consider CNS histoplasmosis in the differential diagnosis in atypical

146 he time of death can result in donor-derived histoplasmosis in the recipient.

147 te has one of the highest death rates due to histoplasmosis in the world, where the mortality rate va

148 es in 88.8% of patients with acute pulmonary histoplasmosis in this assay, while immunodiffusion, com

149 Using a mouse model of histoplasmosis in which both Th1 and Th17 responses cont

150 de a framework for the early pathogenesis of histoplasmosis in which yeast cell invasion of lung MPhi

151 ularization in patients with presumed ocular histoplasmosis, in particular that of subfoveal localiza

152 cases of opportunistic infection, including histoplasmosis, in patients treated with these products.

153 Histoplasmosis incidence rates were elevated among non-H

154 four significant adverse events: a suspected histoplasmosis infection; two Tenchkoff dialysis cathete

155 Research Databases to identify patients with histoplasmosis (International Classification of Diseases

156 mosis with cholestatic jaundice to highlight histoplasmosis involvement in the liver.

157 Presumed ocular histoplasmosis involves the classic triad of discrete at

158 CD4+ T cells in histoplasmosis IRIS demonstrated a significant polyfunct

159 cases of histoplasmosis, 4 of whom developed histoplasmosis IRIS.

160 Histoplasmosis is a common infection endemic in many reg

161 Histoplasmosis is a common infection in the central Unit

162 Histoplasmosis is a known complication of systemic immun

163 Histoplasmosis is a major AIDS-defining illness in Latin

164 Hcd histoplasmosis is a severe fungal infection for which th

165 Histoplasmosis is a worldwide-distributed deep mycosis t

166 Histoplasmosis is among the main acquired immunodeficien

167 Histoplasmosis is an important systemic fungal infection

168 The diagnosis of histoplasmosis is based on a multifaceted approach that

169 Establishing diagnosis of latent and active histoplasmosis is challenging.

170 Where histoplasmosis is common, attributing B-glucan positivit

171 al presentation, diagnosis, and treatment of histoplasmosis is discussed.

172 Isolated CNS histoplasmosis is exceedingly rare.

173 gal meningitis, its role in the treatment of histoplasmosis is hampered by reduced activity and poten

174 Reactivation histoplasmosis is largely a result of impaired immunity,

175 The outcome of central nervous system (CNS) histoplasmosis is often unfavorable.

176 cholestatic granulomatous hepatitis in liver histoplasmosis is rarely seen.

177 nazole is increasingly used as treatment for histoplasmosis; it has in vitro activity against Histopl

178 nazole is increasingly used as treatment for histoplasmosis; it has in-vitro activity against Histopl

179 s included serious infections, tuberculosis, histoplasmosis, listeriosis, and malignancy.

180 sent a rare case of primary gastrointestinal histoplasmosis manifesting with acute granulomatous hepa

181 illance suggests that acute life-threatening histoplasmosis may complicate immunotherapy with TNFalph

182 Histoplasmosis may complicate tumor necrosis factor (TNF

183 In murine histoplasmosis, mice lacking CCR5 or endogenous CCL4 hav

184 osis: Illinois, Kentucky, and West Virginia; histoplasmosis: Missouri, Iowa, and Oklahoma) that do no

185 kDa (Hsp60) that modify disease in a murine histoplasmosis model.

186 ar manifestations of malaria, cysticercosis, histoplasmosis, mucormycosis, subacute sclerosing panenc

187 diasis (n = 10), cryptococcosis (n = 9), and histoplasmosis (n = 11) revealed three antigens with rel

188 s treated with infliximab, manifestations of histoplasmosis occurred within 1 week to 6 months after

189 ransplant (SOT), we report a large series of histoplasmosis occurring after SOT.

190 ted histoplasmosis, primary gastrointestinal histoplasmosis of the liver in absence of lung involveme

191 on three patients who developed disseminated histoplasmosis on therapy with TNF-alpha inhibitors.

192 While much is known about histoplasmosis, only a single virulence factor has been

193 No reactivity was detected with sera from histoplasmosis or blastomycosis patients.

194 Active histoplasmosis or undiagnosed and presumably asymptomati

195 sera from patients with coccidioidomycosis, histoplasmosis, or blastomycosis.

196 a valuable asset to support the diagnosis of histoplasmosis, particularly when direct detection metho

197 vestigate its potential for the follow-up of histoplasmosis patients during treatment, antigen titers

198 Some histoplasmosis patients experienced severe disease, appa

199 cognized by antibodies in 18 of 18 sera from histoplasmosis patients, but not by antibodies in sera f

200 formance for management of immunocompromised histoplasmosis patients.

201 elayed diagnosis of progressive disseminated histoplasmosis (PDH) results in high mortality rates.

202 -2017 for blastomycosis, coccidioidomycosis, histoplasmosis, pneumonia (viral, bacterial, Streptococc

203 -2017 for blastomycosis; coccidioidomycosis; histoplasmosis; pneumonia (viral, bacterial, Streptococc

204 Herein, we report a case of isolated CNS histoplasmosis presenting with pontine stroke and mening

205 liver involvement is common in disseminated histoplasmosis, primary gastrointestinal histoplasmosis

206 .6-2.2) rates in 2013, for blastomycosis and histoplasmosis, respectively.

207 e the understanding of genetic influences on histoplasmosis, reveal how shifts in the composition of

208 Histoplasmosis should be considered early in the evaluat

209 Histoplasmosis should be considered in immunosuppressed

210 c areas, screening for latent or subclinical histoplasmosis should be implemented before antiretrovir

211 Sera from four patients with disseminated histoplasmosis showed falls in antigen levels; three of

212 In contrast, in secondary histoplasmosis, significant elevations of IL-4 and -10 w

213 Low rates of histoplasmosis-specific testing also suggest incidental

214 The Verteporfin in Ocular Histoplasmosis study evaluated photodynamic therapy for

215 MD) (12), macular hole (10), presumed ocular histoplasmosis syndrome (6), proliferative diabetic reti

216 Presumed ocular histoplasmosis syndrome classically presents with atroph

217 streaks, and idiopathy, and presumed ocular histoplasmosis syndrome is still under investigation.

218 roidal neovascularization in presumed ocular histoplasmosis syndrome or age-related macular degenerat

219 macular degeneration or the presumed ocular histoplasmosis syndrome or retinal neovascularization fr

220 Presumed ocular histoplasmosis syndrome remains a significant cause of v

221 The pathogenesis of presumed ocular histoplasmosis syndrome remains mysterious; although som

222 (age-related macular degeneration or ocular histoplasmosis syndrome).

223 al for patients with angioid streaks, ocular histoplasmosis syndrome, and idiopathic causes of choroi

224 surgery in the management of presumed ocular histoplasmosis syndrome, however.

225 n Histoplasma capsulatum and presumed ocular histoplasmosis syndrome, other reports document nearly i

226 ed debate on the etiology of presumed ocular histoplasmosis syndrome, there have been significant adv

227 shown to be associated with Presumed Ocular Histoplasmosis Syndrome-related choroidal neovasculariza

228 he blinding complications of presumed ocular histoplasmosis syndrome.

229 reatment of complications of presumed ocular histoplasmosis syndrome.

230 cularization associated with presumed ocular histoplasmosis syndrome.

231 s), endemic fungal infections (mucormycosis, histoplasmosis, talaromycosis, sporotrichosis), and ende

232 insurance claims data to better characterize histoplasmosis testing and treatment practices and its b

233 usly shown in a murine model of disseminated histoplasmosis that IL-12, IFN-gamma, and TNF-alpha were

234 With use of a murine model of histoplasmosis, this study establishes that methamphetam

235 In reinfection histoplasmosis, treatment with anti-IL-12 MAb did not al

236 In murine histoplasmosis, tumor necrosis factor alpha (TNF-alpha)

237 Assay performance as an aid for diagnosing histoplasmosis was assessed in a prospective cohort of 8

238 Voriconazole in histoplasmosis was associated with increased mortality i

239 Voriconazole in histoplasmosis was associated with increased mortality i

240 A case of acute histoplasmosis was defined as an influenza-like illness

241 herapy while she was living in an area where histoplasmosis was endemic was thought to be the most li

242 terleukin (IL)-12 on the course of pulmonary histoplasmosis was examined in naive and immune mice.

243 hotericin B monotherapy for treatment of CNS histoplasmosis was not supported by this study.

244 was comparable to that of tuberculosis, and histoplasmosis was potentially responsible for preventab

245 In this study, histoplasmosis was reactivated by the depletion of CD4 a

246 erapy with 10 mg/kg of L-AmB in AIDS-related histoplasmosis was safe.

247 production of nitric oxide during secondary histoplasmosis was similar in both groups.

248 Histoplasmosis was the most common IFI type.

249 A murine model of CNS histoplasmosis was used to evaluate the hypothesis that

250 vision loss in patients with presumed ocular histoplasmosis, well defined extrafoveal or juxtafoveal

251 atients with acute pulmonary or disseminated histoplasmosis were also positive.

252 individuals with culture- and antigen-proven histoplasmosis were evaluated using the LAMP assay.

253 Nine cases of histoplasmosis were identified: 2 disseminated and 7 pul

254 presenting with different clinical forms of histoplasmosis were monitored at regular intervals for u

255 Both patients with disseminated histoplasmosis were taking tumor necrosis factor alpha i

256 healthy persons (n = 10) without evidence of histoplasmosis were used as assay controls.

257 ated macular degeneration or presumed ocular histoplasmosis, whereas both alpha v beta 3 and alpha v

258 HPH mutant was avirulent in a mouse model of histoplasmosis, whereas the vma1/VMA1 strain was as path

259 to develop either disseminated or pulmonary histoplasmosis while receiving systemic immunosuppressiv

260 Ten percent of patients died due to histoplasmosis with 72% of deaths occurring in the first

261 ublished cases of biopsy-proven disseminated histoplasmosis with cholestatic jaundice to highlight hi

262 rrently available laboratory diagnostics for histoplasmosis, with an emphasis on complexities of test

263 reasing incidence rates of blastomycosis and histoplasmosis, with increasing diagnoses outside of his

264 esented by PLHIV who presented an episode of histoplasmosis within 6 months after antiretroviral ther